Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Accounts Payables: 2010-2024

Historic Accounts Payables for Anika Therapeutics (ANIK) over the last 15 years, with Dec 2024 value amounting to $5.6 million.

  • Anika Therapeutics' Accounts Payables fell 30.46% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 million, marking a year-over-year decrease of 30.46%. This contributed to the annual value of $5.6 million for FY2024, which is 9.32% down from last year.
  • As of FY2024, Anika Therapeutics' Accounts Payables stood at $5.6 million, which was down 9.32% from $6.2 million recorded in FY2023.
  • Anika Therapeutics' Accounts Payables' 5-year high stood at $9.1 million during FY2022, with a 5-year trough of $5.6 million in FY2024.
  • Moreover, its 3-year median value for Accounts Payables was $6.2 million (2023), whereas its average is $7.0 million.
  • Per our database at Business Quant, Anika Therapeutics' Accounts Payables skyrocketed by 134.45% in 2020 and then plummeted by 31.74% in 2023.
  • Over the past 5 years, Anika Therapeutics' Accounts Payables (Yearly) stood at $9.0 million in 2020, then dropped by 15.04% to $7.6 million in 2021, then increased by 18.88% to $9.1 million in 2022, then slumped by 31.74% to $6.2 million in 2023, then declined by 9.32% to $5.6 million in 2024.